Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 500

Document Document Title
JP2006526025A
The composite and method for treating the mammals disease characterized by the blood vessel rebirth which is not desirable by prescribing for the patient the compound denoted by general formula (I) (a variant is defined in a specificatio...  
JP2006524202A
8beta* vinyl *11beta (omega* substitution of was done) アルキル * S truck *1 of general formula (I) in which the present invention has ERbeta* antagonist activity, 3, 5 (10) * トリエン, It is related with those use for generation...  
JP2006522028A
How to change steroidal 17beta* carboxylic acid into the ester like Calvo thio acid and full チカゾン propionate.  
JP2006521335A
The present invention A steroid ring system and *OH, a スルファ mate machine, a phosphonate machine, Are an included compound arbitrary R bases chosen from any one of a チオホスホネート machine, a スルホネート machine, ...  
JP3824636B2  
JP2006151994A
To provide a simple method for converting a pregnane-3,20-dione compound into a 3α-hydroxy-3β-substituted-pregnane.An unprotected dione is chemoselectively and stereoselelctively converted into a 3(R)-pregnane-3-spiro-2'-oxiran-20-one ...  
JP2006503813A
The new synthetic pathway for generation of the precursor for generation of the compound which has the general formula 8, 10, and 12 is indicated. The general formula 4 and the compound of B are generated in a microbiologic reaction duri...  
JP2005533851A
The present invention offers new HMG*CoA レダクターゼ prevention medicine. In a suitable mode, the HMG*CoA レダクターゼ prevention medicine by the present invention can be inactivated to a primary inactivity metabolite with h...  
JP3715673B2
PURPOSE: To stereoselectively provide a synthetic intermediate to give an oxa- vitamin D having a not-natural steric configuration at 20-position corresponding to vitamin D by a novel reductive alkylation of the ketone of the 20-position...  
JP3710470B2  
JP2005530679A
The present invention 17-ヒドロキシ- 21-ester EPO キシド denoted by the formula II, Are the 21-ester 17-dihydroxy 6alpha-fluorination compound which makes react to a stereoselective fluorinating agent and is stereoselectively den...  
JP2005527496A
According to one mode of the present invention, the medicine tablet for inhalation medication which has a remedially useful effect in the medical treatment of the inflammation obstacle of a breathing tube over the period of 24 hours or m...  
JP2005527497A
In the crystalline complex in which a crystalline lattice contains the compound of formula (I) with stable existence of a guest molecule, The crystalline complex in which the above-mentioned crystalline complex is characterized by being ...  
JP2005527475A
The present invention offers a useful pharmacological compound in the medical treatment of II type diabetes. Since these compounds are easily metabolized by the metabolic medicine detoxification system, they are advantageous. The thiazol...  
JP2005524680A
The method for manufacture of 6alpha* フルオロステロイド including a reaction with the organic base which has a ジアゾ imine machine in the organic solvent in which corresponding 6beta* フルオロステロイド, or 6alpha ...  
JP2005523267A
By the present invention, the inside of the glucocorticoid [化 1] [type of formula (I) as (a) medicine, R shows the heterocyclic aromatic ring of 5 members containing 1*3 hetero atoms chosen from ethyl or O, N, and S, and may be replace...  
JP2005521673A
The medicine tablet containing the water suspension thing of the particle-like compound of formula (I) or its solvation thing is offered. [化 1]  
JP2005519925A
(i) the compound of formula (I) as a medicine or its solvation thing, and (ii) -- the aerosol drug for medicines characterized by the compound or its solvation thing of formula (I) dissolving completely into a tablet is offered including...  
JPWO2003051903A1
一般式(I)[式中、R1は、低級アルキル 基を示し、Xは、酸素原子又はメチレン基を 示し、mは、1から10の整数を示し、nは 、0から5の整数を示す。]で表される...  
JP2005104862A
To obtain a therapeutic agent which has an excellent therapeutic effect on aged macular degeneration.This aged macular degeneration therapeutic agent is characterized by containing a progesterone derivative represented by formula (1) (R1...  
JP2005508934A
How to adjust an androgen receptor on an organization selection target in the patient for whom the compound of the structural formula of a definition on these specifications needs regulation, And it is indicated by the method of activati...  
JP2004537499A
The composite and the method that are the composite and method for treating the mammals disease characterized by the blood vessel rebirth which is not desirable by prescribing the derivative of the 2* methoxy oestradiol of general formul...  
JP2004534795A
Full メタゾン (a [6], 9a*ジフルオロ*11beta, a [17], and 21* トリヒドロキシ *16a* methyl *プレグナ*1, 4*ジエン*3, 20* Xeon), How to be the method of preparing full メタゾン 21* acetate or its 17* carboxyl Andros...  
JP3584050B2  
JP2004533417A
Especially the present invention relates to the corticosteroid for the medical treatment of the illness which may be improved by reinforcement of an epithelium / adhesion between substrates, and use of fluticasone propionate.  
JP2004528364A
When the present invention medicates a vomeronasal organ official with a 17* methylene Andros Than *3alpha* all analog, it offers especially that it is useful as an anti-depression medicine as a corticotropin releasing hormone (CRH) inhi...  
JP2004512359A
The present invention relates to these use for treating the condition of the new medicine composites which use the anti-Kolin action medicine and corticosteroid as a base, these production methods, and the respiratory system.  
JP2004504403A
The present invention relates to a process for the preparation of a compound of formula (I) which comprises the following step: wherein step (a) comprises oxidation of a solution containing the compound of formula (II) wherein the soluti...  
JP2004501930A
a formula useful as medicine -- the compound of [化 1 [the inside of a formula and R are 1 value annular organic groups which have three to 15 atoms in a ring system] ].  
JP2003531200A
(57) Summary book invention offers a useful pharmacological compound in the medical treatment of II type diabetes. Since these compounds are easily metabolized by the metabolic medicine detoxification system, they are advantageous. The t...  
JP3445271B2  
JP2003517472A
(57) Summary book invention relates to 3* methylene steroid derivative which has a general formula (1) for treating an arthritis disease and/or an autoimmune disease, or its prodrug. Among type, when beta* EPO キシド is formed togethe...  
JP2003513102A
(57) Summary book invention has high affinity by estrogen receptor manufacture of the Latt prostate gland rather than estrogen receptor manufacture of the Latt womb by in vitro one, general formula (I) (the inside R of a formula --) as a...  
JP2003511462A
(57) The process of summary book invention changes steroid ketone of formula (III) into and Rosta *4* エン *17beta* carboxylic acid (IV) by a reaction with KSOKHSOKSO. 化 1  
JP2003048895A
To provide a determination method for absolute configuration of an optically active substance capable of determining an absolute configuration in the case of an amorphous compound or a sample of reduced amount. This method provides a con...  
JP3378245B2  
JP2002543216A
(57) The interaction of the steroid derivative of summary book invention can be carried out to a core liver X receptor (LXR) and a maldistribution nature receptor (UR), and it can be used for the medical treatment of various LXR interven...  
JP2002540119A
(57) Summary book invention offers the composite consisting of the steroid of the formula 1, for example, a 16alpha-ブロモ- 3beta-ヒドロキシ- 5alpha-Andros タン- 17-オンヘミ hydrate, and 1, or two or more diluent bases, and...  
JP2002539135A
(57) Summary book invention relates to the knowledge which the natural steroid for using it as the androgen, i. E. , the steroid characterized by arrangement with opposite 14alpha and 17beta, does not expect. The steroid of the present i...  
JP3346873B2  
JP2002322168A
To provide pharmaceutical compounds which reduce undesirable effects occurred at the region where is apart from the target site.Pharmaceutical compounds represented by general formula (I) or their salts or solvates, which are effective i...  
JP3340514B2  
JP2002302476A
To provide a method for simply producing an α-arylalkyl nitrile deriva tive useful as a biologically active compound, e.g. a phosphodiesterase(PDE)-IV inhibitor or a Ca antagonist or their synthetic intermediates from a styrene derivati...  
JP3328938B2  
JP2002531397A
(57) The derivative of such a compound in which summary book invention is collectively defined as "a compound of the present invention" in 17-ketosteroid compound and this specification, The use in the object which needs the disposal of ...  
JP2002531407A
(57) summary book invention the salt (it is collectively defined as "the compound of the present invention") of these compounds that can be used for 17-ketosteroid compound and its derivative, a metabolic product, a precursor, and a medi...  
JP2002234897A
To provide a new compound that bears an ether bond and an epoxy group on the side chain because vitamin D and derivatives thereof have important physiological activity and proliferation inhibitory action, but it has undesirable side effe...  
JP3310301B2  
JP3295426B2  
JP2002502404A
(57) Summary book invention R among a general formula (I) type, Are (H, OR), (H, OSOH), or NOR, and;R, Independently, are H, (C) アルキル, or (C) アシル, and;R and R are hydrogen or (C) アルキル, and, respectively;n, Are 0, 1,...  

Matches 251 - 300 out of 500